-
2023-505766-28-00
10
2022-10-10
Hereditary angioedema
-
2022-500461-28-06
5
2022-09-15
High-Risk Metastatic Hormone-Sensitive Prostate Cancer
-
2023-507518-28-00
5
2022-09-13
Acute myeloid leukemia
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2024-512972-36-00
9
2019-05-23
Indolent B-Cell Non-Hodgkin Lymphoma
-
2023-504694-20-00
9
2017-01-13
pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukem
-
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia
-
2025-524580-21-00
10
2026-06-01
Grass pollen induced allergic rhinitis or rhinoconjunctivitis
-
2025-522091-84-00
4
2026-05-29
Merkel Cell Carcinoma
-
2025-523602-33-00
9
2026-05-13
Advanced or unresectable Hepatocellular Carcinoma (HCC)
-
2025-523797-17-00
4
2026-05-08
Moderate-to-Severe Plaque Psoriasis
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2022-501458-13-01
4
2026-04-29
Advanced Stage of Classic Hodgkin Lymphoma
-
2025-522567-15-00
5
2026-04-28
Plaque Psoriasis
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-522440-41-00
4
2026-04-27
Hidradenitis Suppurativa
-
2025-522705-37-00
4
2026-04-21
HIDRADENITIS SUPPURATIVA
-
2025-523557-33-00
4
2026-04-20
Moderate-to-Severe Hidradenitis Suppurativa
-
2024-513174-22-00
4
2026-04-14
Atrophic Age-related Macular Degeneration (AMD)
-
2025-523085-24-00
5
2026-04-13
Biliary Tract Cancer
-
2025-522403-17-00
5
2026-04-10
Nummular Dermatitis
-
2025-523263-37-00
10
2026-04-08
Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-522578-35-00
4
2026-03-30
Atopic Dermatitis